NS2 consistently produced clinically meaningful effects in reducing the severity of ichthyosis. NS2 is specifically designed to reduce levels of toxic aldehydes, and is the first therapy to be directed at the putative cause of SLS. The symptoms of SLS are thought to be related to high levels of toxic fatty aldehydes due to genetic mutations in fatty aldehyde dehydrogenase, an enzyme critical for the normal function of skin and other organs. Patients with SLS, a rare inborn error of aldehyde metabolism, suffer from ichthyosis, a debilitating dermatologic disease characterized by dry, thickened, scaly skin. I am excited about these results, and I am particularly excited for SLS patients and their caregivers." "The data from this trial suggest that NS2, when applied topically to the skin, has the potential to help patients suffering from SLS by lowering toxic aldehyde levels and preventing the dermal dysfunction that causes ichthyosis. William Rizzo, the principal investigator of the trial and a leading expert in SLS. "The results of this randomized and controlled clinical trial represent a significant advance in the effort to develop a treatment for SLS," said Dr. ( NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported positive data from a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatologic NS2, a novel aldehyde trap, for the treatment of the dermal manifestations of Sjögren-Larsson Syndrome (SLS). LEXINGTON, MA-(Marketwired - Aug 9, 2016) - Aldeyra Therapeutics, Inc.
0 kommentar(er)
